Efficacy of oral irinotecan against neuroblastoma xenografts

Anti-Cancer Drugs

Volumn 8, Issue 4, 1997, Pages 313-322

  Thompson, Joyce ^a   Zamboni, William C ^a   Cheshire, Pamela J ^a   Richmond, Lois ^a   Luo, Xiaolong ^a   Houghton, Janet A ^a   Stewart, Clinton F ^a,b   Houghton, Peter J ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Irinotecan; Neuroblastoma; Xenograft

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0030974770     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199704000-00002     Document Type: Article

References (34)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97.
2. Wang JC. Recent studies of DNA topoisomerases. Biochim Biophys Acta 1987; 909: 1-9.
3. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1990; 34: 98-107.
4. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992; 31: 229-39.
5. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-1-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944-7.
6. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 1988; 21: 308-12.
7. Bissery MC, Mathieu-Boué A, Lavelle E. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Ass Cancer Res 1993; 33: 402.
8. Bissery MC, Mathieu-Boué A, Lavelle F. Experimental activity of CPT-11 in vitro and in vivo. Ann Oncol 1992; 3(suppl 1): 93.
9. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-8.
10. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boue A, Houghton JA. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase inhibitor 9-dimethylaminomethyl-10-hydroxy-camptothecin. Cancer Res 1993; 53: 2823-9.
11. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393-403.
12. Komuro H, Li P, Tsuchida Y, et al. Effects of CPT11 (a unique DNA topoisomerase 1 inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med Pediatr Oncol 1994; 23: 487-92.
13. Vassal G, Morizet J, Bissery M-C, et al. Activity of the camptothecin analogue CPT-11 (Irinotecan) against neuroblastoma xenografts. Med Pediatr Oncol 1994; 23: 207 (abstr).
14. Wiseman LR, Markham A. Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52: 606-23.
15. Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials with the topoisomerase I inhibitors. Semin Oncol 1993; 19: 663-9.
16. Gupta E, Lastingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-5.
17. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68: 777-82.
18. Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small cell lung cancer. J Clin Oncol 1994; 12: 90-6.
19. Shinkai T, Arioka H, Kunikane H, et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer. Cancer Res 1994; 54: 2636-42.
20. Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5FU) in metastatic colorectal cancer. Proc Am Ass Clin Oncol 1993; 12: 196 (abstr).
21. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of irinotecan (CPT-11) and etoposide (E) with G-CSF in advanced lung cancer. Proc Am Ass Clin Oncol 1993; 12: 133 (abstr).
22. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994; 12: 1833-41.
23. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1996; in press.
24. Houghton PJ, Houghton JA, Myers L, Cheshire PJ, Howbert JJ, Grindey GB. Evaluation of N-(5-indanylsulfonyl)-N-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol 1989; 25: 84-8.
25. Rivory LP, Robert J. Reversed-phase high-performance liquid chromatography method for the simultaneous quantification of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in palsma. J Chromatogr Biol Biomed Appl 1994; 661: 133-41.
26. Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 1996, in press.
27. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley 1980.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-81.
29. Lehman E. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day 1975.
30. Houghton PJ, Steward CF, Zamboni WC, et al. Schedule-dependent efficacy of camptothecins in models of human cancer. Ann NY Acad Sci 1996; 803: 188-201.
31. Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anti-Cancer Drugs 1996; 7: 437-60.
32. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-4.
33. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6.
34. Drengler R, Burris H, Dietz A, et al. A phase I trial to evaluate orally administered irinotecan HCl (CPT-11) given daily × 5 every 3 weeks in patients with refractory malignancies. Proc Am Soc Clin Oncol 1996; 15: 489 (abstr).